
    
      This study is proposed under part of the post-Premarket Approval (PMA) requirements. This
      study is a prospective, non-randomized, open-label, multicenter study. It will be performed
      at 10-30 centers in the US and enroll a maximum of 400 subjects. Subjects will be followed
      for a total of five years.
    
  